Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRX4204 + erlotinib
- Development stage
- Unknown
- Lead developer
- Io Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IRX4204 + erlotinib is a combination therapy under clinical investigation, primarily for advanced non-small cell lung cancer (NSCLC). IRX4204 is a highly selective, potent agonist of Retinoid X Receptor (RXR), a nuclear receptor involved in regulating gene expression. Erlotinib is a well-established epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The combination aims to inhibit multiple cancer cell growth pathways synergistically. Preclinical data suggest the combination may overcome resistance mechanisms and provide additive anti-proliferative effects, affecting signaling pathways including Src, PI3K/AKT, ribosomal S6, AMPK, TGF-β, and angiogenesis. IRX4204 is developed by IO Therapeutics and is orally administered, as is erlotinib.
- Other names
- IRX4204IRX-4204IRX 4204erlotinib hydrochloride
02
Targets
RXRA (Retinoid X receptor alpha)SRC (Proto-oncogene tyrosine-protein kinase Src)EGFR (Epidermal growth factor receptor)AKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on IRX4204 + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRX4204 + erlotinib.